Skip to Main Content

Author Details

Yardena Samuels
Weizmann Institute of Science
1998
104
50
PMIDPaper TitleJournal TitlePublished Year
36203013Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.Nat Biotechnol2023
36203013Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors.Nat Biotechnol2023
38077050Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion.bioRxiv2023
37415076The landscape of T cell antigens for cancer immunotherapy.Nat Cancer2023
37217651The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.Nat Cancer2023
36828127Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes.Mol Cell Proteomics2023
38077050Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion.bioRxiv2023
37217651The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.Nat Cancer2023
37415076The landscape of T cell antigens for cancer immunotherapy.Nat Cancer2023
36828127Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes.Mol Cell Proteomics2023
35105962Mechanisms of immune activation and regulation: lessons from melanoma.Nat Rev Cancer2022
36304112NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membrane.iScience2022
35380639Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.Clin Cancer Res2022
35105962Mechanisms of immune activation and regulation: lessons from melanoma.Nat Rev Cancer2022
35380639Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally.Clin Cancer Res2022
36304112NRas activity is regulated by dynamic interactions with nanoscale signaling clusters at the plasma membrane.iScience2022
33355187MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.Cancer Res2021
33545064Melanoma models for the next generation of therapies.Cancer Cell2021
34166618Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.Cell Rep2021
33731925Identification of bacteria-derived HLA-bound peptides in melanoma.Nature2021
33355187MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.Cancer Res2021
33328638Anti-tumour immunity induces aberrant peptide presentation in melanoma.Nature2021
34651586Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.J Clin Invest2021
34941392Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Science2021
33545064Melanoma models for the next generation of therapies.Cancer Cell2021
33731925Identification of bacteria-derived HLA-bound peptides in melanoma.Nature2021
34941392Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Science2021
34651586Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.J Clin Invest2021
34166618Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.Cell Rep2021
33328638Anti-tumour immunity induces aberrant peptide presentation in melanoma.Nature2021
31549767A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.Pigment Cell Melanoma Res2020
32060274Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma.Nat Commun2020
32657358PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem.Bioinformatics2020
31549767A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.Pigment Cell Melanoma Res2020
32060274Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma.Nat Commun2020
32657358PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem.Bioinformatics2020
30465205Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.Methods Mol Biol2019
30478445RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma.Oncogene2019
30465205Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.Methods Mol Biol2019
31522890UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.Cell2019
30914429Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.Cancer Res2019
30863494Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.Oncotarget2019
30742905PIK3CA in cancer: The past 30 years.Semin Cancer Biol2019
30858388Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.Sci Rep2019
30905807Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities.J Invest Dermatol2019
30850615Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.Sci Rep2019
31522890UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.Cell2019
30742905PIK3CA in cancer: The past 30 years.Semin Cancer Biol2019
30863494Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.Oncotarget2019
30858388Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.Sci Rep2019
  • 1 - 50 of 208

Recommended Authors

Simone Lubrano
Moores Cancer Center, University of California
Career Start Year 2015
Number of shared co-authors 8
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 1
Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 2
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year 2012
Number of shared co-authors 0
Giuseppina Claps
Institut National de la Sante et de la Recherche Medicale (INSERM) U
Career Start Year 2010
Number of shared co-authors 10
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 8
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 16
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 13
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Career Start Year 2003
Number of shared co-authors 0
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 12
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 5
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 17
Mairin Rafferty
Oncomark Ltd.
Career Start Year 2001
Number of shared co-authors 3
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 8
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 6
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 4
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 7
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 5
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 16
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year 1997
Number of shared co-authors 8
Woong-Yang Park
Samsung Genome Institute, Samsung Medical Center
Career Start Year 1995
Number of shared co-authors 0
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 9
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 24
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 4
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 12
Grant A McArthur
University of Melbourne
Career Start Year 1986
Number of shared co-authors 18
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 24
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Career Start Year 1982
Number of shared co-authors 19
Menashe Bar-Eli
The University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 6

Collaborators

Steven A Rosenberg
University of Colorado School of Medicine
Co-authored papers 30
Jared J Gartner
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 20
Jimmy C Lin
National Human Genome Research Institute, US National Institutes of Health
Co-authored papers 18
Todd D Prickett
National Cancer Institute
Co-authored papers 12
Xiaomu Wei
Cornell University
Co-authored papers 11
Victor E Velculescu
Co-authored papers 11
Arie Admon
Co-authored papers 10
Abdel G Elkahloun
National Human Genome Research Institute
Co-authored papers 8
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Eytan Ruppin
National Cancer Institute
Co-authored papers 8
Kenneth W Kinzler
Co-authored papers 7
Bert Vogelstein
Co-authored papers 7
Jeffrey E Gershenwald
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Nicholas K Hayward
QIMR Berghofer Medical Research Institute
Co-authored papers 7
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 7
Jennifer A Wargo
Co-authored papers 6
Richard A Scolyer
Co-authored papers 5
Julia C Cronin
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 5
Alfredo A Molinolo
University of California
Co-authored papers 5
David A Solomon
University of California san francisco
Co-authored papers 5
Vijay Walia
National Center for Toxicological Research
Co-authored papers 5
Steven E Robinson
University of Colorado Anschutz Medical Campus
Co-authored papers 4
Ken Dutton-Regester
QIMR Berghofer Medical Research Institute
Co-authored papers 4
Mitchell P Levesque
University Hospital Zurich
Co-authored papers 4
Susan R Davis
Co-authored papers 4
Sean Davis
Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington
Co-authored papers 4
John R Wunderlich
National Cancer Institute
Co-authored papers 4
Glenn Merlino
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 4
Elliott H Margulies
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 4
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers 4
Release 1.2